Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CORT Corcept Therapeutics

Post-Mkt 05-11 17:14:07 EDT

51.20

-1.08

-2.07%

盘后51.03

-0.17-0.33%

16:37 EDT

High52.98	Low51.11	Vol1.08M
Open52.92	D1 Closing52.28	Amplitude3.58%
Mkt Cap5.50B	Tradable Cap4.45B	Total Shares107.36M
T/O55.71M	T/O Rate1.25%	Tradable Shares86.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CORT","market":"US","secType":"STK","nameCN":"Corcept Therapeutics","latestPrice":51.2,"timestamp":1778529600000,"preClose":52.28,"halted":0,"volume":1082036,"hourTrading":{"tag":"盘后","latestPrice":51.03,"preClose":51.2,"latestTime":"16:37 EDT","volume":24321,"amount":1245217.68888,"timestamp":1778531823053,"change":-0.17,"changeRate":-0.00332,"amplitude":0.003906},"delay":0,"changeRate":-0.020657995409334322,"floatShares":86875270,"shares":107356686,"eps":0.35,"marketStatus":"Post-Mkt","change":-1.08,"latestTime":"05-11 17:14:07 EDT","open":52.92,"high":52.98,"low":51.11,"amount":55708843.113308,"amplitude":0.035769,"askPrice":52.21,"askSize":38,"bidPrice":46.44,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.35,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1778544000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1081915200000,"exchange":"NASDAQ","adjPreClose":52.28,"preHourTrading":{"tag":"盘前","latestPrice":53.06,"preClose":52.28,"latestTime":"09:29 EDT","volume":216,"amount":11366.33904,"timestamp":1778506156570,"change":0.78,"changeRate":0.01492,"amplitude":0.028498},"postHourTrading":{"tag":"盘后","latestPrice":51.03,"preClose":51.2,"latestTime":"16:37 EDT","volume":24321,"amount":1245217.68888,"timestamp":1778531823053,"change":-0.17,"changeRate":-0.00332,"amplitude":0.003906},"volumeRatio":0.888432,"impliedVol":0.7698,"impliedVolPercentile":0.7689},"requestUrl":"/m/hq/s/CORT","defaultTab":"news","newsList":[{"id":"2633924535","title":"Corcept CEO Joseph Belanoff disposes 40,000 shares worth $2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633924535","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633924535?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:37","pubTimestamp":1778013455,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics CEO Joseph K. Belanoff sold 40,000 common shares on May 1, 2026.Sale priced at USD 50.1 per share on a weighted-average basis.Holdings fell to 2,878,326 shares, held indirectly via Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDLfsYNP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept CEO Joseph Belanoff disposes 40,000 shares worth $2 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1559883803.SGD","LU0566484027.USD","BK4532","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633603609","title":"Corcept Therapeutics Signals Big Growth After Key Wins","url":"https://stock-news.laohu8.com/highlight/detail?id=2633603609","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633603609?lang=en_us&edition=fundamental","pubTime":"2026-05-05 08:20","pubTimestamp":1777940449,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (($CORT)) has held its Q1 earnings call. Read on for the main highlights of the call. Corcept Therapeutics’ latest earnings ca...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/corcept-therapeutics-signals-big-growth-after-key-wins?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/corcept-therapeutics-signals-big-growth-after-key-wins?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LU0566484027.USD","CORT","BK4532","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632355930","title":"Canaccord Genuity Remains a Buy on Corcept Therapeutics (CORT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2632355930","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632355930?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:16","pubTimestamp":1777893382,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Edward Nash reiterated a Buy rating on Corcept Therapeutics today and set a price target of $110.00. According to TipRank...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-corcept-therapeutics-cort-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-corcept-therapeutics-cort-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0566484027.USD","LU1559883803.SGD","CORT","BK4532","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632328299","title":"Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2632328299","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632328299?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:23","pubTimestamp":1777890180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CORT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 04, 2026 06:23 ET (10:23 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632993289","title":"Corcept Therapeutics price target raised to $75 from $60 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2632993289","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632993289?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:17","pubTimestamp":1777889851,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Corcept Therapeutics (CORT) to $75 from $60 and keeps a Buy rating on the shares. The firm says L...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-price-target-raised-to-75-from-60-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-price-target-raised-to-75-from-60-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632934403","title":"Corcept Therapeutics Inc. : H.c. Wainwright Raises Target Price to $75 From $60","url":"https://stock-news.laohu8.com/highlight/detail?id=2632934403","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632934403?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:10","pubTimestamp":1777889446,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nAZN4SU3W5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1559883803.SGD","CORT","BK4532","BK4007","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632623940","title":"Is Corcept Therapeutics (CORT) Pricing Make Sense After Recent Volatility In The Share Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2632623940","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632623940?lang=en_us&edition=fundamental","pubTime":"2026-05-02 05:47","pubTimestamp":1777672023,"startTime":"0","endTime":"0","summary":"If you are wondering whether Corcept Therapeutics at around US$51.42 is attractively priced or already stretched, starting with a clear view of valuation can help frame your next move.\nThe stock has seen sharp swings recently, with returns of 11.6% over 7 days, 22.5% over 30 days, 34.6% year to date, but a 29.3% decline over the past year and gains of 113.6% over 3 years and 143.7% over 5 years.\nRecent coverage has focused on how this price history shapes expectations for Corcept...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/is-corcept-therapeutics-cort-pricing-make-sense-after-recent","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/is-corcept-therapeutics-cort-pricing-make-sense-after-recent","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK4211","CORT","BK4532","LU1559883803.SGD","LU0566484027.USD","BK4007","FCF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632117649","title":"Corcept Therapeutics Is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2632117649","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632117649?lang=en_us&edition=fundamental","pubTime":"2026-05-02 01:46","pubTimestamp":1777657560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CORT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 01, 2026 13:46 ET (17:46 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124193516","title":"Stock Track | Corcept Therapeutics Soars 5.33% Intraday After Piper Sandler Raises Price Target to $88","url":"https://stock-news.laohu8.com/highlight/detail?id=1124193516","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124193516?lang=en_us&edition=fundamental","pubTime":"2026-05-01 22:05","pubTimestamp":1777644341,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (CORT) saw its stock price surge 5.33% during intraday trading on Friday, following a positive analyst update from Piper Sandler.The investment firm raised its price target on...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632611993","title":"Corcept Therapeutics price target raised to $88 from $73 at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2632611993","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632611993?lang=en_us&edition=fundamental","pubTime":"2026-05-01 19:37","pubTimestamp":1777635469,"startTime":"0","endTime":"0","summary":"Piper Sandler raised the firm’s price target on Corcept Therapeutics (CORT) to $88 from $73 and keeps an Overweight rating on the shares following ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-price-target-raised-to-88-from-73-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-price-target-raised-to-88-from-73-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632690996","title":"U.S. RESEARCH ROUNDUP-Caterpillar, Textron, Wesco International","url":"https://stock-news.laohu8.com/highlight/detail?id=2632690996","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632690996?lang=en_us&edition=fundamental","pubTime":"2026-05-01 15:29","pubTimestamp":1777620570,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Caterpillar, Textron, Wesco InternationalMay 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nL8N41E08S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIO","AXSM","DDOG","CROX","BIIB","OWL","BK4022","COP","LU1169590202.USD","CHH","BR","SAM","CERS","CFR","CARR","CAT","DAR","BELFA","CVNX","BEZ","BEX","COLM","DOGD","CVNY","AESI","CAH","CBZ","ATI","BEG","CCB","CABO","IE00B2B36J28.USD","CI","CTOS","CAR","BMY","BLDR","BK4123","DXCM","BDC","BE","CVNA","CAKE","CLX","DASX","DASH","AX","CORT","COHU","BBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632093699","title":"Corcept Therapeutics Inc : Piper Sandler Raises Target Price to $88 From $73","url":"https://stock-news.laohu8.com/highlight/detail?id=2632093699","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632093699?lang=en_us&edition=fundamental","pubTime":"2026-05-01 11:17","pubTimestamp":1777605420,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nFWN41E008:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0566484027.USD","CORT","LU1559883803.SGD","BK4007","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632660190","title":"Corcept Therapeutics Swings to Loss, Says ALS Drug Didn't Meet Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2632660190","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632660190?lang=en_us&edition=fundamental","pubTime":"2026-05-01 06:47","pubTimestamp":1777589220,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics swung to a loss in the first quarter and said a Phase 2 study of an ALS treatment failed to meet its primary endpoint.The pharmaceutical company said Thursday that the trial of dazucorilant didn't meet a primary endpoint of a difference in function between patients who received the treatment and a placebo group.Despite missing the endpoint, the company said patients who received a higher dose of the drug for a two-year period had an 87% reduction in the risk of death. Overall survival was a secondary endpoint for the study, Corcept said.\"Our data demonstrate that dazucorilant markedly reduces mortality in the first years following diagnosis, when people with ALS retain meaningful function and quality of life,\" Corcept Chief Development Officer Bill Guyer said. \"We are working with regulators to advance this program as expeditiously as possible and expect to initiate a pivotal Phase 3 study later this year.\". Shares of Corcept were up 1% to $47.00 in after-hours tra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","BK4532","BK4007","LU0566484027.USD","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632642946","title":"Corcept Therapeutics announced 2-year OS data from Phase 2 dazucorilant study","url":"https://stock-news.laohu8.com/highlight/detail?id=2632642946","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632642946?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:06","pubTimestamp":1777583197,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (CORT) “announced two-year overall survival data from the Phase 2 DAZALS study of its proprietary, selective cortisol modulato...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-announced-2-year-os-data-from-phase-2-dazucorilant-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-announced-2-year-os-data-from-phase-2-dazucorilant-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT","LU0566484027.USD","BK4007","BK4532","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632669179","title":"Corcept Q1 revenue rises but misses analyst estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2632669179","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632669179?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:34","pubTimestamp":1777581242,"startTime":"0","endTime":"0","summary":"Corcept Q1 revenue rises but misses analyst estimatesOverviewU.S. drugmaker's Q1 revenue rose yr/yr but missed analyst expectationsCompany posted Q1 net loss as operating expenses increased for Lifyor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nL1N41D1NI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4532","LU1559883803.SGD","CORT","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632858661","title":"Earnings Flash (CORT) Corcept Therapeutics Posts Q1 Per Share Loss $-0.30","url":"https://stock-news.laohu8.com/highlight/detail?id=2632858661","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632858661?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:28","pubTimestamp":1777580902,"startTime":"0","endTime":"0","summary":"Earnings Flash (CORT) Corcept Therapeutics Posts Q1 Per Share Loss $-0.30","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632966912","title":"GUIDANCE: (CORT) Corcept Therapeutics Expects 2026 Revenue Range $950M-$1.05B, vs. FactSet Est of $899.5M","url":"https://stock-news.laohu8.com/highlight/detail?id=2632966912","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632966912?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:22","pubTimestamp":1777580560,"startTime":"0","endTime":"0","summary":"GUIDANCE: (CORT) Corcept Therapeutics Expects 2026 Revenue Range $950M-$1.05B, vs. FactSet Est of $899.5M","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632864669","title":"Corcept Q1 turns to USD 31.8 million net loss; revenue rises to USD 164.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2632864669","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632864669?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:21","pubTimestamp":1777580497,"startTime":"0","endTime":"0","summary":"Corcept posted a net loss of USD 31.8 million in first quarter 2026, swinging from net income a year earlier.Operating loss widened to USD 49.6 million as operating expenses climbed to USD 214.5 million, due to higher spending to prepare for Lifyorli launch and to invest in Cushing’s syndrome growth initiatives.Cash and investments slipped to USD 515.4 million at March 31, 2026, while Lifyorli  gained FDA approval in March for platinum-resistant ovarian cancer.Corcept raised 2026 revenue guidance to USD 950 million-USD 1.05 billion.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL1tgHY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0566484027.USD","BK4532","CORT","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632666715","title":"Corcept says Phase 2 ALS study shows 87% lower death risk with dazucorilant","url":"https://stock-news.laohu8.com/highlight/detail?id=2632666715","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632666715?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:19","pubTimestamp":1777580377,"startTime":"0","endTime":"0","summary":"Corcept released two-year survival follow-up from Phase 2 DAZALS trial of dazucorilant in amyotrophic lateral sclerosis.Exploratory analyses indicated patients initially treated with higher-dose dazucorilant lived longer than patients on placebo who did not switch to the drug in extension follow-up.Trial missed its primary endpoint on functional decline, raising execution risk despite favorable survival signal.Corcept expects to start a pivotal Phase 3 study later this year as it discusses next steps with regulators.Program update included continued acceptable safety profile, with gastrointestinal discomfort cited as most common side effect.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDLYbpF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1559883803.SGD","LU0566484027.USD","BK4532","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632665636","title":"Corcept Therapeutics Q1 EPS $(0.30) Misses $(0.16) Estimate, Sales $164.903M Miss $192.510M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2632665636","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632665636?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:05","pubTimestamp":1777579547,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (NASDAQ:CORT) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.16) by 87.5 percent. This is a 276.47 percent decrease over earnings of $0.17 per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/04/52194379/corcept-therapeutics-q1-eps-0-30-misses-0-16-estimate-sales-164-903m-miss-192-510m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Therapeutics Q1 EPS $(0.30) Misses $(0.16) Estimate, Sales $164.903M Miss $192.510M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corcept.com","stockEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.2486},{"period":"3month","weight":0.2804},{"period":"6month","weight":-0.2908},{"period":"1year","weight":-0.2676},{"period":"ytd","weight":0.5023}],"compareEarnings":[{"period":"1week","weight":0.0235},{"period":"1month","weight":0.0911},{"period":"3month","weight":0.0681},{"period":"6month","weight":0.0993},{"period":"1year","weight":0.3054},{"period":"ytd","weight":0.0817}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.022337},{"month":2,"riseRate":0.409091,"avgChangeRate":0.008661},{"month":3,"riseRate":0.772727,"avgChangeRate":0.140734},{"month":4,"riseRate":0.545455,"avgChangeRate":0.005665},{"month":5,"riseRate":0.521739,"avgChangeRate":0.012108},{"month":6,"riseRate":0.454545,"avgChangeRate":0.039099},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.006529},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.006283},{"month":9,"riseRate":0.454545,"avgChangeRate":0.062175},{"month":10,"riseRate":0.5,"avgChangeRate":-0.005789},{"month":11,"riseRate":0.5,"avgChangeRate":0.018834},{"month":12,"riseRate":0.409091,"avgChangeRate":0.027449}],"exchange":"NASDAQ","name":"Corcept Therapeutics","nameEN":"Corcept Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Corcept Therapeutics,CORT,Corcept Therapeutics股票,Corcept Therapeutics股票老虎,Corcept Therapeutics股票老虎国际,Corcept Therapeutics行情,Corcept Therapeutics股票行情,Corcept Therapeutics股价,Corcept Therapeutics股市,Corcept Therapeutics股票价格,Corcept Therapeutics股票交易,Corcept Therapeutics股票购买,Corcept Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}